Eli Lilly Reports Strong Q1 Earnings and Raises Full-Year Guidance Amid Mounjaro Growth
Eli Lilly (LLY) reported first-quarter adjusted EPS of $8.55, exceeding expectations by over $2 billion in revenue from its drug Mounjaro alone. The company raised full-year guidance for both earnings per share and revenue due to strong performance across tirzepatide franchises.
Topics: Barclays analysis GLP-1 drugs Mounjaro pharmaceuticals Zepbound